Build the evidence pathway before launch
AIM4ALL works with Pharmaceutical Manufacturers early in the product lifecycle to complement clinical trial findings with high-quality, structured and governance-compliant real-world data.
Data can be collected from therapy-eligible patients before and after launch, supporting a clearer understanding of care pathways, unmet need, implementation requirements and real-world outcomes.
Areas of collaboration
Evidence planning: agree clinical datasets, outcomes and HTA-relevant data elements.
Pathway readiness: standardise relevant care pathways and identify implementation barriers.
Digital data collection: establish efficient, reliable and governance-compliant processes.
Real-world insights: provide appropriate pseudonymised evidence to support decision-making.
Contract design: establish the evidence foundation for value-based agreements.
Pricing visibility: work with Remedium Capital towards more acceptable MFN net launch pricing.